Three drug combinations for late-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Uganda

Gerardo Priotto, Carole Fogg, Manica Balasegaram, Olema Erphas, Albino Louga, Francesco Checchi, Salah Ghabri, Patrice Piola, Gerardo Priotto, Carole Fogg, Manica Balasegaram, Olema Erphas, Albino Louga, Francesco Checchi, Salah Ghabri, Patrice Piola

Abstract

Objectives: Our objective was to compare the efficacy and safety of three drug combinations for the treatment of late-stage human African trypanosomiasis caused by Trypanosoma brucei gambiense.

Design: This trial was a randomized, open-label, active control, parallel clinical trial comparing three arms.

Setting: The study took place at the Sleeping Sickness Treatment Center run by Médecins Sans Frontières at Omugo, Arua District, Uganda

Participants: Stage 2 patients diagnosed in Northern Uganda were screened for inclusion and a total of 54 selected.

Interventions: Three drug combinations were given to randomly assigned patients: melarsoprol-nifurtimox (M+N), melarsoprol-eflornithine (M+E), and nifurtimox-eflornithine (N+E). Dosages were uniform: intravenous (IV) melarsoprol 1.8 mg/kg/d, daily for 10 d; IV eflornithine 400 mg/kg/d, every 6 h for 7 d; oral nifurtimox 15 (adults) or 20 (children <15 y) mg/kg/d, every 8 h for 10 d. Patients were followed up for 24 mo.

Outcome measures: Outcomes were cure rates and adverse events attributable to treatment.

Results: Randomization was performed on 54 patients before enrollment was suspended due to unacceptable toxicity in one of the three arms. Cure rates obtained with the intention to treat analysis were M+N 44.4%, M+E 78.9%, and N+E 94.1%, and were significantly higher with N+E (p = 0.003) and M+E (p = 0.045) than with M+N. Adverse events were less frequent and less severe with N+E, resulting in fewer treatment interruptions and no fatalities. Four patients died who were taking melarsoprol-nifurtimox and one who was taking melarsoprol-eflornithine.

Conclusions: The N+E combination appears to be a promising first-line therapy that may improve treatment of sleeping sickness, although the results from this interrupted study do not permit conclusive interpretations. Larger studies are needed to continue the evaluation of this drug combination in the treatment of T. b. gambiense sleeping sickness.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Trial Profile
Figure 1. Trial Profile
Footnotes are as follows. aOral report of death compatible with HAT. bControlled at 14 mo: favorable evolution, died later during uterus surgery. cControlled at 6 and 15 mo, respectively: favorable evolution, both moved away later. dControlled at 6 mo: favorable evolution, died later of snake bite.

References

    1. Pepin J, Milord F, Khonde AN, Niyonsenga T, Loko L, et al. Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg. 1995;89:92–97.
    1. World Health Organization. WHO Technical Report Series 881. Geneva: WHO; 1998. Control and surveillance of African trypanosomiasis: Report of a WHO expert committee.120
    1. Burri C, Keiser J. Pharmacokinetic investigations in patients from northern Angola refractory to melarsoprol treatment. Trop Med Int Health. 2001;6:412–420.
    1. Legros D, Evans S, Maiso F, Enyaru JC, Mbulamberi D. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg. 1999;93:439–442.
    1. Stanghellini A, Josenando T. The situation of sleeping sickness in Angola: A calamity. Trop Med Int Health. 2001;6:330–334.
    1. Janssens PG, De Muynck A. Clinical trials with “nifurtimox” in African trypanosomiasis. Ann Soc Belg Med Trop. 1977;57:475–480.
    1. Moens F, De Wilde M, Ngato K. [Clinical trial of nifurtimox in human African trypanosomiasis] Ann Soc Belg Med Trop. 1984;64:37–43.
    1. Pepin J, Milord F, Meurice F, Ethier L, Loko L, et al. High-dose nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness: An open trial in central Zaire. Trans R Soc Trop Med Hyg. 1992;86:254–256.
    1. Van Nieuwenhove S. Advances in sleeping sickness therapy. Ann Soc Belg Med Trop. 1992;72(Suppl 1):39–51.
    1. Burri C, Nkunku S, Merolle A, Smith T, Blum J, et al. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: A randomised trial. Lancet. 2000;355:1419–1425.
    1. Pepin J, Khonde N, Maiso F, Doua F, Jaffar S, et al. Short-course eflornithine in Gambian trypanosomiasis: A multicentre randomized controlled trial. Bull World Health Organ. 2000;78:1284–1295.
    1. Schmid C, Nkunku S, Merolle A, Vounatsou P, Burri C. Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness. Lancet. 2004;364:789–790.
    1. National Cancer Institute, Cancer Therapy Evaluation Program, National Institutes of Health. Common toxicity criteria, version 2.0. 1999. Available: . Accessed: 09 November 2006.
    1. Eze MO. Towards more efficacious chemotherapy of trypanosomiasis: Combination of alpha-difluoromethylornithine (DFMO) with reactive oxygen generating drugs. Med Hypotheses. 1991;36:246–249.
    1. Fairlamb AH, Henderson GB, Bacchi CJ, Cerami A. In vivo effects of difluoromethylornithine on trypanothione and polyamine levels in bloodstream forms of Trypanosoma brucei . Mol Biochem Parasitol. 1987;24:185–191.
    1. Abeloff MD, Slavik M, Luk GD, Griffin CA, Hermann J, et al. Phase I trial and pharmacokinetic studies of alpha-difluoromethylornithine—An inhibitor of polyamine biosynthesis. J Clin Oncol. 1984;2:124–130.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться